SNL BioSolutions ApSAktiv

CVR 44569272

Økonomiske nøgletal

-606.994 kr.+60,7%
Bruttofortjeneste 2025
-2 mio.-1,5 mio.-1 mio.-500 t.020242025

Nøgletal

2025
Balancens sammensætning
OmsætningsaktiverAnlægsaktiverGæld og hensatte forpligtelserEgenkapital
02 mio.4 mio.6 mio.20242025

Selskabsskat

Virksomheden er sambeskattet. Skatten opgøres samlet hos administrationsselskabet Dayanand Jadhav Holding ApS.

Kilde: Skattestyrelsens offentlige skattelister for selskaber. Beregnet skat for indkomståret; kan være lavere end 22 % af indkomsten, fx ved skat betalt i udlandet. sktst.dk

Regnskabstal2024–2025
20242025
Balance — aktiver
Likvide beholdninger751.471499.544
Omsætningsaktiver i alt880.981572.615
Anlægsaktiver i alt—98.806
Aktiver i alt880.981671.421
Balance — passiver
Kortfristede gældsforpligtelser111.145527.060
Langfristede gældsforpligtelser4.620.0004.851.000
Gældsforpligtelser i alt4.731.1455.378.060
Selskabskapital46.316469.507
Overført resultat-3.896.480-5.652.955
Årets resultat-3.896.480-1.756.475
Egenkapital i alt-3.850.164-4.706.639
Resultatopgørelse
Bruttofortjeneste-1.543.476-606.994
Resultat af primær drift-3.685.291-2.266.804
EBITDA—-2.255.826
Resultat før skat-3.896.480-2.494.955
Årets resultat-3.896.480-1.756.475
Personaleomkostninger2.141.8151.648.832
Af- og nedskrivninger—10.978
Andre nøgletal
Ansatte63

En streg (—) betyder, at der ikke er indsendt årsrapport, eller at posten ikke fremgår af den; 0 er et nul angivet i årsrapporten.

Om virksomheden

Årsrapport 2025

Business reviewThe purpose of the company is to conduct business in trade, services, and production, among other things, with a significant positive impact on society and the environment as a whole.

Financial review The company's income statement for the year ended 31 December 2025 shows a loss of DKK 1.756.475, and the balance sheet at 31 December 2025 shows negative equity of DKK 4.706.639.Uncertainty about the continued operation (going concern)The company has lost its entire share capital, which is in line with management’s expectations. It is expected that the share capital will be re-established through operations once the development project has been completed. The company is financially supported by the company’s ultimate owner, who has issued a letter of support valid until the date of approval of the annual report for the financial year ended 31 December 2026. On this basis, management considers that the annual report may be prepared on a going concern basis. Reference is made to Note 1 "Uncertainty related to going concern".

Uddrag af ledelsesberetningen i den seneste årsrapport.

SNL BioSolutions ApS — cvrprofil.dk